Brief Title
Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
Official Title
A Phase II Study Investigating Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
Brief Summary
PEBBLE is an open-label, international, multicentre, window of opportunity phase II trial
that aims to evaluate the effects of short-term preoperative therapy with bintrafusp alfa in
patients with histologically confirmed urothelial carcinoma requiring radical surgery with
bilateral pelvic lymph node dissection. Eligible patients will receive 4 doses of bintrafusp
alfa (1200mg flat dose) at 14 day intervals before undergoing radical surgery. Patients will
attend study visits at 6, 12 and 24 weeks following their surgery. After the 24-week
post-surgical visit, patients will enter a follow up phase during which they will be
contacted annually for 2 years after their surgery to collect survival and disease status
data. The efficacy of bintrafusp alfa will be assessed on CT/MRI scan images and tumour
tissue samples collected at baseline and after treatment with bintrafusp alfa.
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Pathological complete response rate (pCRR)
Secondary Outcome
Dynamic changes in TGFb, T-effector signatures and CD8 count measured in tumour samples.
Condition
Transitional Cell Carcinoma
Intervention
Bintrafusp alfa
Study Arms / Comparison Groups
Bintrafusp alfa
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
49
Start Date
June 2021
Completion Date
January 2025
Primary Completion Date
July 2023
Eligibility Criteria
Inclusion Criteria:
1. Willing and able to provide written informed consent
2. Ability to comply with the protocol
3. Age ≥ 18 years
4. Histopathologically confirmed urothelial carcinoma (T2-T4aN0-1M0) of the bladder where
radical cystectomy with bilateral pelvic lymph node dissection is indicated. Patients
with "variant histology" such as micropapillary, plasmocytoid, nested, sarcomatoid,
microcystic, squamous and adeno variants of urothelial carcinoma are required to have
more than 50% of tumor tissue with transitional cell pattern.
5. Residual disease after TURBT or endoscopy (surgical opinion, cystoscopy or
radiological presence).
6. Fit and planned for surgery (according to local guidelines).
7. N0-1 and M0 disease CT or MRI (within 4 weeks of enrolment). Patients with N2 disease
on cross sectional imaging are excluded from the study.
8. Representative formalin-fixed paraffin embedded (FFPE) tumour samples with an
associated pathology report that are determined to be available and sufficient for
central testing.
9. Patients who refuse neoadjuvant cisplatin-based chemotherapy or in whom neoadjuvant
cisplatin-based therapy is not appropriate.
10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
11. Negative serum pregnancy test within 14 days of Day 1 Cycle 1 for female patients of
childbearing potential.
12. Highly effective method of contraception throughout the study until 2 months after the
last dose of bintrafusp alfa for female patients of childbearing potential and 4
months after the last dose of bintrafusp alfa for male patients.
13. Adequate haematologic and end-organ function within 4 weeks prior to the first study
treatment.
Exclusion Criteria:
1. Pregnant and lactating female patients.
2. Major surgical procedure within 4 weeks prior to enrolment or anticipation of need for
a major surgical procedure during the course of the study other than for diagnosis.
3. Previous intravenous chemotherapy or immune therapy for bladder cancer.
4. Patients with prior allogeneic stem cell or solid organ transplantation.
5. Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or
anti-PD-L1 therapeutic antibody or pathway-targeting agents.
6. Has received any prior radiotherapy to the bladder.
7. Patients must not have had oral or intravenous (IV) steroids for 14 days prior to
Cycle 1 Day 1. The use of inhaled corticosteroids, physiologic replacement doses of
glucocorticoids (i.e., for adrenal insufficiency), and mineralocorticoids (e.g.,
fludrocortisone) is allowed at physiologic doses ≤ 10 mg/day of prednisone or
equivalent.
8. Received therapeutic IV antibiotics within 14 days prior to enrolment (Patients
receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection
or chronic obstructive pulmonary disease) are eligible).
9. Administration of a live, attenuated vaccine within 4 weeks prior to enrolment or
anticipation that such a live, attenuated vaccine will be required during the study.
Seasonal flu vaccines that do not contain a live virus are permitted.
10. Treatment with systemic immunostimulatory agents (including but not limited to
interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug,
whichever is shorter, prior to enrolment.
11. Treatment with any other investigational agent or participation in another clinical
trial with therapeutic intent within 4 weeks prior to enrolment.
12. Evidence of significant uncontrolled concomitant disease that could affect compliance
with the protocol or interpretation of results, including significant liver disease
(such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava
syndrome).
13. Malignancies other than urothelial carcinoma of the bladder within 3 years prior to
enrolment with the exception of those with a negligible risk of metastasis or death
and treated with expected curative outcome (such as adequately treated carcinoma in
situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ
treated surgically with curative intent) or localized prostate cancer treated with
curative intent and absence of prostate-specific antigen (PSA) relapse or incidental
prostate cancer (Gleason score ≤ 3 + 4 and PSA < 10 ng/mL undergoing active
surveillance and treatment naive).
14. Severe infections within 4 weeks prior to enrolment including but not limited to
hospitalisation for complications of infection, bacteraemia, or severe pneumonia.
15. Significant cardiovascular disease, such as New York Heart Association cardiac disease
(Class II or greater), myocardial infarction within 6 months prior to enrolment,
unstable arrhythmias, or unstable angina.
16. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced
pneumonitis, organising pneumonia (i.e., bronchiolitis obliterans, cryptogenic
organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
(History of radiation pneumonitis in the radiation field (fibrosis) is permitted).
17. Patients with uncontrolled Type 1 diabetes mellitus. Patients with Type 1 diabetes
controlled on a stable insulin regimen are eligible.
18. Patients with active hepatitis infection (defined as having a positive hepatitis B
surface antigen [HBsAg] test at screening) or hepatitis C. Patients with past
hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a
negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc]
antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody
are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
19. Positive test for HIV.
20. Patients with active tuberculosis.
21. History of autoimmune disease including but not limited to myasthenia gravis,
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
multiple sclerosis, vasculitis, or glomerulonephritis. Patients with diabetes type I,
vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive
treatment are eligible. Replacement therapy (eg, thyroxine, insulin, or physiologic
corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not
considered a form of systemic treatment and is allowed. Patients with a history of
autoimmune-related hypothyroidism, unless on a stable dose of thyroid-replacement
hormone.
22. History of bleeding diathesis or recent major bleeding events (i.e. Grade ≥ 2 bleeding
events in the 30 days prior to treatment
23. Has a diagnosis of immunodeficiency.
24. Receiving chronic systemic steroid therapy (in doses exceeding 10 mg daily of
prednisone equivalent) or any other form of immunosuppressive therapy within 7 days
prior to the first dose of study drug.
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Thomas Powles, +44 (0) 2078828764, [email protected]
Administrative Informations
NCT ID
NCT04878250
Organization ID
PEBBLE
Responsible Party
Sponsor
Study Sponsor
Queen Mary University of London
Study Sponsor
Thomas Powles, Principal Investigator, Queen Mary University of London
Verification Date
May 2021